Clinical Trials Logo

Lymphoepithelioma-Like Carcinoma clinical trials

View clinical trials related to Lymphoepithelioma-Like Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04430166 Not yet recruiting - Clinical trials for Lymphoepithelioma-Like Carcinoma

PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

Lymphoepithelioma-like carcinoma (LELC) may benefit from immunocheckpoint inhibitor therapy. Although target antibody drugs for PD-1 and PD-L1 have achieved good results in immunotherapy of many malignant tumors, there is still a lack of corresponding clinical research reports on whether LELC treatment can benefit. Therefore, this study intends to adopt the basket research model , to explore the application of anti-procedural death receptor 1 (PD-1) monoclonal antibody in patients with advanced LELC after the failure of first-line standard treatment . Further explore the relationship between tumor and body immunity, tumor microenvironment and curative effect, and find stable biomarkers, so as to screen out the superior population of tumor immunotherapy.